Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

The Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) was developed to improve clinician’s ability to predict the prognosis of a PSC patient.

Using clinical and laboratory data from about 500 PSC patients seen at Mayo Clinic, PREsTo could predict the percent of liver decompensation in a PSC patient at five years. The prediction calculation takes into account several variables (see figure below). Results were validated using data obtained from about 300 PSC patients seen at the University of Oslo in Norway. The tool not only is a step forward in terms of predicting disease progression, it also can be used to stratify patients in future clinical trials for PSC.

To read more about how the score is calculated, and to calculate the score of a patient with PSC, click on the link below.

The PREsTo score does not work for every patient with PSC as stated in the disclaimer on the webpage linked below.

Calculate your PREsTo score.

2018-09-19-PREsTo Graphic